JAAD:儿童病期白癜风的发病率和特应性皮炎、自身免疫性疾病和银屑病风险的增加相关性研究

2022-03-22 医路坦克 MedSci原创

儿童期白癜风(COV)被定义为12岁之前发生的白癜风,本文研究分析了COV患者与年龄和性别匹配的健康人相比的发病率和并发疾病的风险,

    儿童期白癜风(COV)被定义为12岁之前发生的白癜风。为了确定COV患者与年龄和性别匹配的健康人相比的发病率和并发疾病的风险,我们通过获取2007年1月至2018年12月记录的NHI索赔数据进行了一项全国性的横断面研究。

   用SAS软件6.1版对所有数据进行分析。统计分析包括泊松回归和多因素Logistic回归。多重比较采用Benjamini-Hochberg法。两组比较,差异有统计学意义(P<0.05)。

   2010-2018年期间COV发病率为50.3/100,000人年。2010年至2018年年发病率呈上升趋势(P<0.001)。女性发病率显著高于男性(P<0.001)。

   在调整了年龄、性别和合并疾病后,患有COV的患者患特应性皮炎的风险显著增加,但患过敏性鼻炎的风险降低。我们还发现冠状病毒与各种疾病有显著的相关性,包括Graves病、桥本氏甲状腺炎、红斑狼疮、吗啡、类风湿性关节炎、斑秃、荨麻疹和银屑病。在按性别进行的亚组分析中,仅在女性中观察到COV与Graves病和红斑狼疮之间的关联。

   先前的研究表明,与晚发型白癜风患者相比,COV患者患特应性皮炎的风险更高。在这项研究中,我们发现COV患者患特应性皮炎的风险比健康对照组更高。过敏性鼻炎的矛盾结果可能是由于过敏性鼻炎的过度诊断造成的,因为过敏性鼻炎的发病率非常高。

图1.儿童期白癜风的年发病率。

图2.儿童期发病的白癜风与共病疾病之间的关系的森林图。*按性别和年龄调整。CI=可信区间;OR=赔率比

 

   只有几项研究报道了自身免疫性疾病与COV之间的关联,报告COV患者的自身免疫性疾病的风险低于晚发白癜风患者。然而,基于我们的结果,COV患者自身免疫性疾病的风险不应被忽视,需要密切监测。

   这是第一项以人群为基础的研究,以确定COV患者并发疾病的发生率和相关性。冠状病毒与上述疾病之间的关联表明,白癜风患者存在易感免疫学背景,而不是自身免疫。

 

文献来源:Lim JH,  Lew BL,  Sim WY, Incidence of childhood-onset vitiligo and increased risk of atopic dermatitis, autoimmune diseases, and psoriasis: A nationwide population-based study.J Am Acad Dermatol 2022 Mar 08;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1838055, encodeId=1b9c18380559a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jan 08 08:03:34 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823807, encodeId=db16182380e0c, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 25 23:03:34 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580188, encodeId=db7e158018818, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Wed Mar 23 16:03:34 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205082, encodeId=649d1205082b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa35218798, createdName=147760b0m84暂无昵称, createdTime=Wed Mar 23 00:24:17 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1838055, encodeId=1b9c18380559a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jan 08 08:03:34 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823807, encodeId=db16182380e0c, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 25 23:03:34 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580188, encodeId=db7e158018818, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Wed Mar 23 16:03:34 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205082, encodeId=649d1205082b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa35218798, createdName=147760b0m84暂无昵称, createdTime=Wed Mar 23 00:24:17 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1838055, encodeId=1b9c18380559a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jan 08 08:03:34 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823807, encodeId=db16182380e0c, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 25 23:03:34 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580188, encodeId=db7e158018818, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Wed Mar 23 16:03:34 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205082, encodeId=649d1205082b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa35218798, createdName=147760b0m84暂无昵称, createdTime=Wed Mar 23 00:24:17 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1838055, encodeId=1b9c18380559a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Jan 08 08:03:34 CST 2023, time=2023-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823807, encodeId=db16182380e0c, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Feb 25 23:03:34 CST 2023, time=2023-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580188, encodeId=db7e158018818, content=<a href='/topic/show?id=bd2529020e1' target=_blank style='color:#2F92EE;'>#免疫性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29020, encryptionId=bd2529020e1, topicName=免疫性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df0516593209, createdName=124988c7m100暂无昵称, createdTime=Wed Mar 23 16:03:34 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205082, encodeId=649d1205082b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa35218798, createdName=147760b0m84暂无昵称, createdTime=Wed Mar 23 00:24:17 CST 2022, time=2022-03-23, status=1, ipAttribution=)]
    2022-03-23 147760b0m84暂无昵称

    学习了

    0

相关资讯

Br J Dermatol:银屑病的快速就诊新模式-PRAC

银屑病是一种复杂的免疫介导性炎症性疾病(IMID),早期干预银屑病可以减少相关预后,这导致了银屑病快速访问诊所(PRAC)的发展,PRAC是一个创新的顾问领导的多学科诊所。

JAAD:免疫检查点抑制剂介导的银屑病治疗

免疫检查点抑制剂(ICIS)使晚期/转移性癌症的治疗发生了革命性的变化。ICI诱导的新生银屑病和各种表型的既往银屑病的恶化已被广泛报道,为此我们系统地回顾了ICI介导的银屑病的治疗。

Br J Dermatol:肠道微生物区系竟可以影响银屑病?

越来越多的证据支持自身免疫性疾病与肠道微生物区系改变的关联,肠道微生物区系可能在银屑病等免疫介导性疾病中发挥作用,本文进一步调查肠道微生物对银屑病的影响的关系。

JEADV:布达鲁(brodalumab)单抗治疗中重度斑块型银屑病的远期疗效和安全性

银屑病是一种慢性的、免疫调节的疾病,影响着全世界大约1.25亿人。本文评估接受Brodalab单抗治疗的中重度银屑病患者在120周内的疗效、有效率和安全结果。

Allergy:T细胞受体测序表明银屑病是是一种以皮肤为重点的过敏原驱动的疾病

特应性皮炎(AD)和银屑病一个特点是T细胞渗入皮肤。目前尚不清楚这些浸润性T细胞在多大程度上是抗原特异性皮肤归巢T细胞或非特异性异质性旁观者细胞。本文就此进行相关阐述。

J Invest Dermatol:阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病疗效对比

本文评估了阿达木单抗联合甲氨蝶呤(ADL-MTX组)与阿达木单抗单独治疗(ADL组)治疗慢性斑块型银屑病的疗效、安全性、药代动力学和免疫原性。